Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III sublingual immunotherapy study for house dust mite allergic rhinitis
2025-523119-12-00Phase 3Authorised
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jan 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of Dermatophagoides pteronyssinus allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy, sponsored by ROXALL Medizin GmbH. Primary endpoint: Mean Combined Symptom and Medication Score during PEEP. Planned start Jan 2026; status: authorised.
02
Drugs
Dermatophagoides pteronyssinus allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2025-523119-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523119-12-00.